Home > PE Ratio > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
PE (Price/Earnings) Ratio

The Current P/E Ratio of GLENMARK PHARMACEUTICALS is -33.64.

Share Price ₹1,025.2Apr 19,2024
Market Cap ₹28,929.7 Cr
Earnings-TTM₹-859.9 CrTTM-Consolidated Results
Price/Earnings-33.64xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of GLENMARK PHARMACEUTICALS is calculated as :

Current Market Cap [ ₹28,929.7 Cr] as on Apr 19,2024

(/) Earnings [ ₹-859.9 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ -33.64x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay -33.64 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.

Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS


PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS

- GLENMARK PHARMACEUTICALS 's latest p/e ratio is -33.64x.

- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 19.62x.

- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.51x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.

- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 7.49x.


How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
GLENMARK PHARMACEUTICALS -859.89-33.6428,929.7
SUN PHARMACEUTICAL INDUSTRIES LTD8,998.6340.60365,311.0
CIPLA LTD3,744.0329.01108,623.0
DR REDDYS LABORATORIES LTD5,209.4019.0399,134.3
ZYDUS LIFESCIENCES LTD2,954.2031.4192,794.9
DIVIS LABORATORIES LTD1,382.9770.4397,408.4
MANKIND PHARMA LTD1,743.3053.6793,565.4
TORRENT PHARMACEUTICALS LTD1,494.0057.4785,858.5
LUPIN LTD1,809.7438.9670,506.8
AUROBINDO PHARMA LTD2,777.8922.9363,697.4
ABBOTT INDIA LTD1,145.5848.4755,528.4

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE -33.64x
Max industry PE 70.43x
Median industry PE 38.96x
Average industry PE 34.40x



You may also like the below Video Courses